A Phase 3 interventional study of Follitropin alfa/lutropin alfa (MBJ-0011) and hMG in Infertility, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Recruiting at 21 sites in Japan. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.
Among the 30 studies testing follitropin alfa in Infertility, this one is the 8th largest by planned enrollment, is one of 2 that started in 2026, is one of 9 in phase 3, and was the 29th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:
Vietnam Military Medical University · Sites in Vietnam
Ages 18–34 · Women only
Nanjing University · Sites in China
Ages 35–40 · Women only
By country, each count listing its studies:
follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 42 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 266 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 159 across the 30 interventional studies. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.
44 studies in Infertility by Merck KGaA, Darmstadt, Germany: 1 open now, 1 under way, 1 of them phase 3. Of 43 finished, 21 (49%) have results posted.
Among the 44 studies in Infertility by Merck KGaA, Darmstadt, Germany, this one is the 6th largest by planned enrollment of the 31 interventional ones that give a count, is the only one that started in 2026, is one of 11 in phase 3, and was the 44th registered.
Merck KGaA, Darmstadt, Germany’s Infertility studies by the year they started, since 1999.
2 of the studies testing follitropin alfa in Infertility that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340827Phase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyA Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) | 2027-09-30 |
| NCT06571214Nanjing UniversityPotential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies testing follitropin alfa in Infertility, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 44 in Infertility:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of follitropin alfa/lutropin alfa in Japanese participants with Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) deficiency undergoing Assisted reproductive technology (ART).
The study duration is approximately 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy in Part A.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive fixed combination product of recombinant Follitropin alfa (rechFSH)/lutropin alfa (rechLH) in a 2:1 ratio.
Combination Product: Follitropin alfa/lutropin alfa (MBJ-0011) · Drug: Cetrorelix acetate · Drug: Coriogonadotropin alfa · Drug: Progesterone gel
Drug: hMG · Drug: Cetrorelix acetate · Drug: Coriogonadotropin alfa · Drug: Progesterone gel
Drug pages: Follitropin alfa · Lutropin alfa
Follitropin alfa and lutropin alfa will be administered subcutaneously once daily with a starting dose of 150 International Unit (IU) of follitropin alfa, 75 IU of lutropin alfa, in ovarian stimulation up to 18 days.
Also known as: MBJ-0011, r-hFSH/r-hLH
Participants will receive 150 IU as solvent, subcutaneously, for solution for injection, daily (up to 18 days) during ovarian stimulation.
Participants will receive 250 micrograms (mcg) of Cetrorelix acetate as Powder for reconstitution to a solution for injection with diluent in ampule, daily from Day 5 or 6 of stimulation up to the day of r-hCG.
Also known as: GnRH, antagonist
Participants will receive 250 mcg of r-hCG, as solution for injection, subcutaneously, during final follicular maturation.
Also known as: r-hCG
Participants will self-administer progesterone gel 8 percent, with an applicator, at a dose of 90 milligram (mg), intravaginally, daily from oocyte retrieval during Luteal phase support.
Total number of oocytes retrieved
Mean number of oocytes retrieved will be calculated. Oocyte retrieval was a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.
Time frame: At approximately 36 to 38 hours after r-hCG administration (Day 4)
Total dose of gonadotropin (IU) used
Total dose of Human Menopausal Gonadotropin (hMG) referred as IU of FSH.
Time frame: At Visit 3 after ovarian stimulation from Day 5 until Day of r-hCG (maximum 18 days)
Number of Days of Gonadotropin Treatment
Total number of days of ovarian stimulation will be reported.
Time frame: At Visit 3 after ovarian stimulation from Day 5-18
Total Number of Follicles Measuring greater than or equal to 14 millimeter (mm) and greater than or equal to 17 mm in diameter
Time frame: During Ovarian stimulation (Day 5 to Day 18)
Serum Estradiol (E2) levels
Time frame: At Visit 3 after ovarian stimulation from Day 5-18
Proportion of 2 Pronuclei Embryos/Fertilized Oocytes
The proportion of oocytes that fertilized after they were inseminated with the sperm will be reported.
Time frame: At 18 (Plus or minus two hours) hours after insemination
Number of blastocysts frozen
After the transfer of 1 fresh blastocysts - spare ones will be frozen.
Time frame: 5 days after insemination
Number of Participants With Clinical Pregnancy
A clinical pregnancy is a pregnancy that is confirmed by both pregnancy test (beta-hCG test) and sonographic confirmation of a gestational sac or with or without heartbeat (fetal sac).
Time frame: 35-42 days after Visit 5 (Blastocyst transfer)
Number of Participants With Ongoing Pregnancy
Ongoing pregnancy will be confirmed with transvaginal ultrasound (TVUS) showing heartbeat.
Time frame: up to 80 days after blastocyst transfer (pregnancy week 11 to 12)
Number of Participants With Treatment-Emergent Adverse Events and Treatment related Adverse Events
Time frame: 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy
Number of Participants With Ovarian Hyperstimulation Syndrome (OHSS)
Time frame: 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy
Number of Participants With Mild, Moderate, and Severe Ovarian Hyperstimulation Syndrome
Time frame: 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy
Number of Cycles Cancelled due to Risk of Ovarian Hyperstimulation Syndrome
Time frame: 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy
Number of Participants With Clinically Significant Changes in Laboratory Parameters and Vital Signs
Time frame: 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy
Number of Participants Experiencing Local Reactions
Pain redness, swelling, bruising, and itching around the injection site will be assessed.
Time frame: 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy
Plan to share: Yes — IPD supporting publicly available results will be evaluated for sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: IPD from completed trials will be publicly available within 6 months after all of the following events: Approval of a product/new indication by major authorities (FDA, EMA, PMDA if requested) with no pending submissions Public results via primary manuscript or trial registry disclosure Legal authority to share data Privacy protections are in place If approval is not sought or development is globally discontinued, data will be publicly available within 18 months after global trial completion. Further information on how to request data can be found on our website bit.ly/IPD21
Access criteria: Qualified researchers may propose access to IPD from sponsored trials via https://vivli.org/members/ourmembers/.
Data sharing details ↗ · vivli.org
Started Feb 2026 (actual). Primary completion is estimated for Sep 2027, 19 months after the start.
Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 19 months is close to that.
Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jul 2028 → Sep 2027 and completion Jul 2028 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Follitropin alfa · Lutropin alfa
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany →